We sought to assess the potential of human cord blood-derived mesenchymal stem cells (CB-MSCs) to derive insulin-producing, glucose-responsive cells. We show here that differentiation protocols based on stepwise culture conditions initially described for human embryonic stem cells (hESCs) lead to differentiation of cord blood-derived precursors towards a pancreatic endocrine phenotype, as assessed by marker expression and in vitro glucose-regulated insulin secretion. Transplantation of these cells in immune-deficient animals shows human C-peptide production in response to a glucose challenge. These data suggest that human cord blood may be a promising source for regenerative medicine approaches for the treatment of diabetes mellitus.
INTRODUCTION
relatively simple to expand under defined conditions. In this respect, the stem cell-rich human umbilical cord blood (CB) represents a promising source for the treat-Current treatments for type 1 diabetes mellitus are based on exogenous administration of insulin via multi-ment of insulinopenic diabetes. We therefore explored the use of human CB-MSCs ple injections and/or delivery through microinfusors. While effective in maintaining reasonable blood glucose as a source of insulin-producing cells through in vitro differentiation with defined stepwise culture protocols. control, these treatments often fail to prevent hyper-and hypoglycemia, potentially resulting in acute events Selected markers that are seen in pluripotent stem cells [octamer-binding transcription factor 4 (OCT4), NANOG, (hypoglycemic episodes) and/or chronic complications. Islet transplantation can restore physiological blood stage-specific embryonic antigens-3 (SSEA-3), SSEA-4, tumor-related antigen (TRA)-1-60, and TRA-1-81] have glucose control and eliminate severe hypoglycemia, improving quality of life (47) .
been described in MSCs from human fetal but not adult sources (20), raising the possibility that adult MSCs may As one of the outstanding issues that characterize islet transplantation is the scarcity of donors, the use not possess sufficient plasticity to differentiate towards insulin-producing β-cells. However, several reports of stem cell-derived insulin-producing cells represents a desirable goal. The hope of obtaining an unlimited demonstrate the expression of these markers in adult stem cells including CB-MSCs (8,10, 16, 19, 26, 41, 50, 52 , source of cells for regenerative medicine was catalyzed by the isolation of human embryonic stem cells (hESCs) 54, 62, 64) . Here we show stable expression of pluripotent stem cell markers in CB-MSCs through 8-10 pas- (55) and adult pluripotent mesenchymal stem cells (MSCs) (25) . Both cell types have therefore received a sages, and we further demonstrate their downregulation after differentiation. great deal of attention as possible sources of insulinproducing cells (1, 15, 21, 27, 39, 40, 43, 51, 57, 59) . Adult Recently, the presence of transcription factors (TFs) implicated in β-cell differentiation has been documented stem cells are obtained from multiple tissues and are in mononuclear cells (MNCs) from CB (45, 46) . We 30% fetal bovine serum (FBS), low dexamethasone (10 −7 M), penicillin (50 U/ml), streptomycin (50 µg/ml), and report here that also CB-MSCs express pancreas-specific TFs prior to differentiation, and we further demonstrate L-glutamine (2 mM) (Invitrogen) and plated out at a concentration of 5-7 × 10 6 cells/ml in T75 culture flasks that these TF are stably maintained for at least 5 passages in vitro.
(BD Biosciences, San Diego, CA). Cells were incubated at 37°C in 5% CO 2 in a humidified atmosphere. When Several studies have demonstrated that CB-MSCs display robust in vitro proliferative capacity without well-developed colonies of adherent, fibroblast-like cells appeared, cultures were washed with PBS, harvested spontaneous differentiation; under appropriate culture conditions, CB-MSCs show the potential to develop into with 0.05% trypsin-EDTA (Invitrogen), and reseeded at 1 × 10 5 cells per flask in the same medium without dexa-mesodermal-, endodermal-, and ectodermal-derived cell subsets (4, 5, 28, 31, 32, 35, 38, 49, 61) . Although a small methasone. When cells reached 80% confluence, they were trypsinized and replated at a 1:3 dilution. Cells number of studies propose that CB-MNCs (13,29,60), "cord blood-derived embryonic-like stem cells" (CBEs) expanded from the colonies from each CB unit were stored as different clones in liquid nitrogen for further (8, 54, 63) , and CB-MSCs (17, 18, 24) can differentiate into insulin-producing cells either in vitro or in vivo, experiments. For each clone, cells from early passages (p3-p5) were used in all experiments. there is still the need to carry out a detailed characterization of CB-derived cells to understand their potential
To study the doubling/generation time, CB-MSCs (isolated from five different CB units) at passage 4 were clinical use.
Our approach, described herein, is based on the use seeded in T25 flasks. The cells from one flask were harvested daily and enumerated (three sets of counting/ of stepwise culture protocols where developmental cues are sequentially provided to CB-MSC to induce differ-flask) for 16 consecutive days by the trypan blue exclusion test. The mean of the counts was calculated and entiation towards the pancreatic endocrine phenotype. While similar protocols were initially defined on hESCs plotted against culture time to generate a growth curve. The population doubling (n) level was obtained by the (7, 34, 42) , our data are the first that suggest their efficacy on CB-MSCs. formula: n = log(N/N o ) × 3.33, where n = number of generations (number of times the cell population doubles After isolation, expansion and characterization of CB-MSCs from fresh CB samples, we successfully during the time interval), N = number of cells at the end of the time interval, and N o = number of cells at the induced CB-MSCs to generate glucose-responsive Cpeptide-secreting cell clusters in vitro. Furthermore, we beginning of a time interval. The generation time (G) was calculated by the formula: G = t/n (G = generation demonstrate glucose-stimulated human C-peptide production in animals that received transplants of partially time; t = time interval in days, hours, or minutes). Karyotyping and fingerprinting were performed at differentiated CB-MSCs (consisting primarily of pancreatic endodermal cells, with few hormone-expressing passages 5 and 35 by cytogenetic standard protocols (Cell Line Genetics, Madison, WI) on one CB-MSC cells). Altogether, our results suggest that CB-MSCs have the potential to differentiate into a β-cell-like phe-clone (clone #51). notype, and respond to glucose stimulation both in vitro Assessment of Multidifferentiation Potential and in vivo. This is also the first report on pancreatic βcell differentiation from MSCs following well-estab-CB-MSCs at passage four were cultured in various differentiation media to assess their differentiation lished stage-wise protocols. potential into adipocytes, osteoblasts, and chondroblasts.
MATERIALS AND METHODS

MesenCult adipogenic medium (for adipogenesis) and Generation and Expansion of MSCs From Fresh
MesenCult . In this study, we refer to CB-MSC differentiation Immunophenotypic analysis of selected cell surface protocols I and II. markers was performed on CB-MSCs (n = 7 clones; CB-CB-MSC differentiation protocol I mimics the five-MSCs isolated from 7 different CB units) at passages stage differentiation protocol (S0-S5) originally described 1-6. The following monoclonal antibodies (mAbs) were by D'Amour et al. (7) . The method is as follows. After used for the immunophenotyping of CB-MSCs: fluoresa brief wash in PBS (with Mg/Ca), the cells were culcein-isothiocyanate (FITC) conjugated Abs CD3 (S4.1), tured in RPMI (without FBS), activin A (100 ng/ml), CD11b (VIM12), CD13 (TÜ K1), CD14 (TÜ K4), CD29 and Wnt3a (25 ng/ml) for the first day. The next day, (MEM-101A), CD31 (MBC78.2), CD34 (581 (class the medium was changed to RPMI with 0.2% v/v FBS III)), CD44 (MEM-85), CD45 (HI30), CD63 (CLBand activin A (100 ng/ml), and the cells were cultured gran/12), and CD80 (MEM-233) were from Invitrogen; for 2 additional days. Next, the cells were briefly CD164 (N6B6) and human leukocyte antigen (HLA)washed with PBS (with Mg/Ca) and then cultured in ABC (G46-2.6) were from BD Biosciences. Phyco-RPMI with 2% v/v FBS, fibroblast growth factor 10 erythrin (PE) conjugated Ab CD4 (S3.5), CD54 (FGF10; 50 ng/ml), and 3-Keto-N-(aminoethyl-amino-(MEM-111), CD56 (MEM-188), CD103 (LF61), CD105 caproyl-dihydrocinnamoyl) (KAAD)-cyclopamine (CYC, (SN6) and CD117 (104D2) were from Invitrogen; 0.25 µM) for 4 days. The medium was then changed to CD49e (IIA1), CD73 (AD2), CD109 (TEA 2/16), DMEM with 1% v/v B27 supplement, all-trans retinoic CD122 (Mik-b3), and HLA-DR (G46-6 (L243)) were acid (RA, 2 µM), CYC (0.25 µM), and FGF10 (50 ng/ from BD Biosciences; CD106 (STA), CD144 (16B1), ml) and cells were cultured for 4 days. For stage 4, the SSEA-3 (eBioMC-631 (MC-631)), SSEA-4 (eBioMCmedium was changed to DMEM with 1% v/v B27 813-70), TRA 1-60 (TRA 1-60), and TRA 1-81 (TRA supplement, N-[N- (3, 5 -difluorophenacetyl)-L-alanyl]-S-1-81) were from eBioscience (San Diego, CA). Allophyphenylglycine t-butyl ester (DAPT; 1 µM) and exendincocyanin (APC) conjugated Ab CD8 (3B5), CD10 4 (50 ng/ml) and cultured for 3 days. For stage 5, cells (MEM-78), CD20 (HI47), CD40 (HB14), and CD86
were cultured for additional 4 days in CMRL with 1% (BU63) were from Invitrogen; CD28 (CD28.2), CD36 v/v B27 supplement, exendin-4 (50 ng/ml), insulin-like (CB38 (NL07)), and CD81 (JS-81), and CD90 (5E10) growth factor (IGF-1; 50 ng/ml), and hepatocyte growth were from BD Biosciences; CD133/1 (AC133) was factor (HGF; 50 ng/ml). from Miltenyi Biotechnology Inc. (Auburn, CA), and
The CB-MSC differentiation protocol II comprises CD184 (12G5) was from eBioscience. Isotype control the above 5 stages, but with modifications as described for each Ab was purchased as suggested from the previously (34) . The first modification eliminates cyclorespective companies.
pamine and substitutes keratinocyte growth factor CB-MSCs were stained with various combinations of (KGF; 50 ng/ml) for FGF10 during stage 2. The second mAbs at the recommended concentration by the manumodification, in stage 3, substitutes Noggin (50 ng/ml) facturer. Cells were detached with 0.05% trypsin-EDTA for FGF10. The third modification eliminates DAPT and (Invitrogen), washed twice with fluorescence-activated exendin-4 at stage 4. In addition, to promote transition cell sorting (FACS) buffer (PBS with 2% FBS, 5 mM to definitive endoderm as described for hESCs (42) , the EDTA and 0.02% sodium azide). A total of 100 µl of PI3K inhibitor LY-294002 (50 µM) was included in CBcell suspension (ϳ5 × 10 5 cells) in FACS buffer was ali-MSC differentiation protocol II for the first 3 days of quoted per tube and appropriately labeled mAbs were culture during stage 1. added and incubated for 30 min at 4°C in the dark. The For both protocols, media with appropriate growth cells were then washed twice and resuspended in FACS factors and supplements were prepared for each stage buffer. Isotype-matched staining with irrelevant Abs was and sequential, daily changes were made. Media and performed to determine background and specificity. Ten supplements were obtained from Invitrogen (RPMI, thousand labeled cells were used for acquisition, and DMEM, B27), R&D Systems (Minneapolis, MN; data were analyzed with CellQuest software on a FACS-Wnt3a, activin A, FGF10, KGF, Noggin, IGF-I), Sigma-Calibur (BD, Becton, Dickinson and Company, Franklin Aldrich (LY-294002, Exendin4, RA), Toronto Research Lakes, NJ).
Chemicals Inc. (Ontario, Canada; KAAD-cyclopamine), and PeproTech Inc., (Rocky Hill, NJ; HGF).
In Vitro Pancreatic Differentiation of CB-MSCs
The differentiation process was characterized at each stage by gene expression by real-time polymerase chain Expanded CB-MSCs from early passages (p3-p5) at 80-90% confluence were induced to differenti-reaction (RT-PCR), and protein expression by immunofluorescence (IF) and flow cytometry. ate towards insulin-secreting cells following protocols
Real-Time Quantitative PCR
temperature. Double IF staining was carried out simultaneously by incubating cells in the mixture of two pri-Before and after differentiation, cells were harvested mary Abs at respective dilutions in blocking buffer in a and total RNA was isolated using Trizol (Invitrogen) humidified chamber overnight at 4°C. After decanting and quantified using an ND-1000 spectrophotometer and washing three times in PBS, the cells were incu-(NanoDrop Technologies, Wilmington, DE). After treatbated in the mixture of two secondary Abs (which are ment with DNase I (Invitrogen), cDNA was synthesized raised in different species with two different fluoroby using random primers with the SuperScript-II RT kit chromes) diluted in blocking buffer in a humidified following the manufacturer's instructions (Invitrogen). chamber for 1 h at room temperature in the dark. After Enough total RNA was converted to cDNA, so that the decanting and washing in PBS in the dark, the cells were final concentration was 3-30 ng in 1.5 µl for each 10 µl counterstained with DAPI (0.1-1.0 µg/ml) (Santa Cruz PCR reaction. Target mRNAs were assayed using Taq-Biotechnology, Santa Cruz, CA) for 5 min and rinsed Man Gene Expression Assays (Applied Biosystems, with PBS. For all experiments, control reactions included: Foster City, CA) ( Table 1) , supplemented with Univer-1) the omission of the primary Ab; 2) the replacement sal PCR Master Mix (Applied Biosystems). PCR reacof the primary Ab with the appropriate isotype-matched tions were performed on an Applied Biosystems ABI irrelevant Ab; and 3) the omission of the secondary Ab. 7500 real-time PCR thermal cycler.
The stained cells were mounted with a drop of SlowFade Gold antifade reagent (Invitrogen).
Immunofluorescence (IF) Analysis
The atic and duodenal homeobox 1 (PDX1), 10 µg/ml (AF2419, R&D Systems); rabbit anti-neurogenein-3 normal serum blocking solution (same species as secondary Ab), normal mouse, goat, rabbit serum (NGN3), 1:500 (ab38548, Abcam Inc., Cambridge, MA); rabbit anti-neurogenic differentiation factor 1 (Invitrogen), or normal donkey serum (Jackson Immuno Research Laboratories Inc., West Grove, PA) at room (NEUROD1), 5 µg/ml (ab38552, Abcam); mouse anti-NK6 homeobox 1 (NKX6.1), 1:500 (F55A12, DSHB); rabbit anti-islet 1 transcription factor (ISL1), 2 µg/ml (ab20670, Abcam); mouse anti-epithelial cadherin Inc., Carpinteria, CA). Alexa-488-, Alexa-555-, and
INS (ILPR) Hs00355773_m1
Alexa-568-conjugated goat and donkey Abs against GCG (GLP1, GLP2) Hs00174967_m1 mouse, rat, rabbit, guinea pig, and goat (Molecular Probes/ PAX6 (AN2) Hs00240871_m1
Invitrogen) were used at 1:500 dilutions.
18S Hs99999901_s1
For fluorescence imaging, a Leica DM IRB microscope (Leica Microsystems, Bannockburn, IL) was used, Source: All from Applied Biosystems. and the images were acquired digitally using a high-capsule. Cells were delivered under the kidney capsule with a PE-50 catheter. The kidney was repositioned and resolution B/W CCD digital camera ORCA-ER (Hamamatsu Corp., Bridgewater, NJ). Fluorescence images the muscular and skin layers sutured. In the sham control group, a cell-free saline injection was made via were also acquired, as needed, on a Zeiss LSM510 confocal microscope (Carl Zeiss Inc., Thornwood, NY).
identical procedures. Quantitative analysis was carried out by counting the Glucose-Stimulated C-Peptide Secretion number of immunoreactive cells and comparing that in Transplanted Mice number to the total number of viable cells as determined by DAPI staining. A minimum of 20 random fields were For the detection of human C-peptide, animals were counted for each marker. Statistical Analysis cells were incubated with KRBH buffer for 1 h as wash-Results are expressed as mean ± SD. Statistical ing. The cells were incubated with KRBH buffer with significance of differences was assessed by the Stu-2.5 mM D-glucose for 1 h and then KRBH buffer with dent's t-test. A value of p < 0.05 was considered statisti-20 mM D-glucose for 1 h. The C-peptide levels in culcally significant. ture supernatants were measured using the Human Ultrasensitive C-peptide enzyme-linked immunosorbent RESULTS assay (ELISA) kit (Mercodia, Uppsala, Sweden) follow-Isolation, Expansion, and Growth Characteristics ing the manufacturer's instructions, and normalized to of CB-MSCs total cellular DNA. Genomic DNA from cells was isolated using PureLink Genomic DNA Mini Kit Out of ϳ250 CB units, 90 were selected based on CB volume (>80 ml; range 40-130 ml) and cell viability (Invitrogen) and quantified using ND-1000 spectrophotometer (NanoDrop).
(>70% viability; range 50-90%) and processed in an attempt to generate MSC colonies. Colonies were suc-In Vivo Experiments cessfully generated from 31 out of the 90 CB units processed (frequency 34.4%). No correlation was detected NOD.CB17-Prkdc scid /J [nonobese diabetic severe combined immunodeficient (NOD-SCID)] mice (7-8 weeks between hours elapsed after CB collection, volume, number of MNCs in the CB, and the success in the gen-old, male) were purchased from the Jackson Laboratory (Bar Harbor, ME) and housed in virus antibody-free eration of MSCs. At 8-25 days (mean 14) after seeding of MNCs, adherent cells of fibroblast-like morphology rooms in microisolator cages with free access to sterilized food and water. All animal manipulations were were detected with a median frequency of five colonies per CB (range 1-18). After the first passage, highly pro-conducted at the Preclinical Cell Processing and Translational Models Core of the Diabetes Research Insti-liferating fibroblast-like cells became predominant over other cell types. Over the following two passages, adher-tute under protocols reviewed and approved by the University of Miami's Institutional Animal Care and ent cells were almost entirely composed of spindleshaped, fibroblast-like cells that later grew to confluence Use Committee.
Partially differentiated CB-MSCs in culture to the in 8-12 days (Fig. 1A) . CB-MSC populations from individual CB units exhibited differences in growth dynam-pancreatic endoderm stage (stage 4 at day 14 from the second differentiation protocol) were used for transplan-ics, from slow growing clones to very rapidly growing ones. Growth curve studies indicated that the cells dou-tation procedures. The cell aggregates were collected by gentle scraping, allowed to settle by gravity and kept bled every ϳ4.6 ± 2.8 days (range 1.6-8.6 days) ( Fig.  1B) . Some CB-MSC clones slowed down proliferation on ice in RPMI containing B-27 serum-free supplement. Slurry of 10-25 µl of cell aggregates (5-7 × 10 6 cells) after passage 7 or 8, whereas other clones could be expanded every 2-3 days for 20-30 passages and in saline solution was delivered either by intraperitoneal (IP) injection, or transplanted under the kidney capsule.
beyond. During the cultures, the nucleus/cytoplasm (N/ C) ratio decreased, suggesting that the cells entered Briefly, under general anesthesia, the left kidney was exposed and a small opening was made in the kidney senescence (data not shown). Fig. 2A ).
CB-MSCs Express the Characteristic MSC Markers
CB-MSCs were negative for macrophage markers (CD11b and CD14), costimulatory molecules (CD28, Phenotypic analyses were performed on different CB-MSC clones cultured from passages 2 through 6 by flow CD40, CD80, and CD86), hematopoietic cell markers (CD34, CD45, CD117, and CD133), adhesion molecules Expanded, Undifferentiated CB-MSCs Express Markers of Pancreatic Endocrine Cells (CD31/PECAM1), endothelial markers (CD36 and CD144), integrin, alpha E (CD103), and major histo-Two recent reports demonstrate that freshly isolated compatibility complex (MHC) class II (HLA-DR) ( Fig. and expanded CB-MNCs express some markers typi-2B). They were also negative for CD3, CD4, and CD8 cally associated with pancreatic development (45,46). (T-cell markers), CD20 (B-cell marker), CD164 (adhe-
To determine if CB-MSCs also comprised such "pansion molecule), and CD184/CXCR4 (endothelial cell creas-committed" subpopulations, immunofluorescence marker/hematopoietic cell marker) (data not shown).
staining for pancreatic endocrine cell markers was carried out in three different CB-MSC clones at early pas-CB-MSCs Express Pluripotent Stem Cell Markers sage levels (p3 and p7). Indeed, we found strong nuclear Several recent publications have demonstrated that, staining for the key pancreatic TFs in a relatively large like hESCs, adult stem cells may also occasionally proportion (30-40% for PDX1, NKX6.1, and ISL1; 70express pluripotent markers such as NANOG, OCT4, 80% for NGN3 and NEUROD1) of CB-MSCs in all SSEA-3, SSEA-4, TRA-1-60, and TRA-1-81 (8,10,16, three clones tested (Fig. 3B ). They also stained positive 19, 26, 41, 50, 52, 54, 62, 64) . In order to determine whether for the MSC cell membrane marker vimentin (Fig. 3B ). this was also the case in CB-MSCs in our study, we
Staining for FOXA2 and SOX17 was negative (data performed additional IF analyses on undifferentiated not shown). Coexpression of vimentin with NGN3, cells. OCT4 was found to be highly expressed in the NEUROD1, and ISL1 was observed in ϳ60-70% of the nucleus of ϳ80-90% of the cells (Fig. 3A) . Staining triple stained cells (Fig. 3C ). for the membrane markers of pluripotency SSEA-3 and
Directed Differentiation of CB-MSCs SSEA-4 was also positive in ϳ30-40% of the cells (Fig.  3A) . Expression of TRA-1-60 and TRA-1-81, in con-Undifferentiated CB-MSCs underwent considerable morphological changes during the various stages of dif-trast, was very weak or undetectable by flow cytometry (data not shown).
ferentiation of protocol I (Fig. 4A, B) . The effects of , neurogenic differentiation factor 1 (NEUROD1), NK6 homeobox 1 (NKX6.1), islet 1 transcription factor (ISL1)], and the mesenchymal marker vimentin (VIM). Coexpression of selected markers is shown in (C) . DAPI (blue) labels cell nuclei. Images were taken from CB-MSCs (clone #51, p3) using a Leica DM IRB inverted microscope (A, C) and an LSM510 confocal microscope (B) (original magnification: 40×). Similar staining results were obtained in three different clones at both passages (p3 and p7) tested.
various treatments on differentiation were initially eval-primitive gut tube (PG) markers hepatocyte nuclear factor 1B (HNF1B) and HNF4A, PE markers PAX4 and uated using real-time PCR to detect gene expression characteristic of each cell population at different stages.
MAFB, and the endocrine cell markers INS, GCG, and PPY could not be detected (Fig. 4C ). CB-MSC to mesendodermal (ME) cell transition from stage 0 to stage 1 was associated with downregulation Figure 5 looks at the second differentiation protocol (Fig. 5A) , which resulted in the development of well-of the pluripotent stem cell marker OCT4 and the epithelial-type cadherin (ECAD). At the same time, there was defined cell clusters at stage 5 (Fig. 5B ). The decrease in the expression of OCT4 and ECAD in stage 1 was upregulation of definitive endoderm (DE) markers [chemokine (C-X-C motif) receptor 4 (CXCR4) and more marked, to the point that these markers were nearly undetectable at stage 3. IF analyses also showed SOX17], posterior foregut endoderm (PF) markers [PDX1 and motor neuron and pancreas homeobox 1 absence of ECAD expression, and upregulation of neural-type cadherin (NCAD) at stage 1, suggesting the (HLXB9)], pancreatic endoderm (PE) markers (NGN3 and NKX6.1), and the immature α/β-cell marker paired transition of CB-MSCs to ME cells (Fig. 6A, B) . Expression of NCAD declined in stage 2 and was not box 6 (PAX6). However, upregulation of most of these markers, with the exception of HLXB9 and NKX6.1 observed in later stages (Fig. 6A) . Expression of the DE markers SOX1 and CXCR4 was observed throughout (40-50-fold), was relatively small (5-12-fold up). The stages 1 and 2, gradually declining from stage 3 onwards observed in stage 1 (data not shown). In stage 2, we observed the expression of the primitive gut marker ( Figs. 5C and 6C ). The DE marker FOXA2 was not seen either at mRNA or protein levels. Positive IF staining HNF4A, but not HNF1B. In stage 3, the cells expressed high levels of PDX1 and HLXB9 while maintaining the for the ME/PE marker goosecoid (GSC) was also were differentiated to ILCs following the differentiation protocol I. Cell samples were collected for each stage at days 1, 4, 8, 12, 15, and 19 and analyzed by qRT-PCR for OCT4, ECAD, SOX17, FOXA2, CXCR4, HNF1B, HNF4A, PDX1, HLXB9, NGN3, PAX4, NKX6.1, PAX6, insulin, and glucagon expression (see Materials and Methods for definitions). All mRNA expression levels were normalized to the housekeeping gene 18S rRNA expression. Relative gene expression (RQ) was determined by normalization to that of undifferentiated CB-MSC sample at stage 0 (S0) in the dataset and the standard deviation of the gene expression measurements was reported. generation. CB-MSCs (n = 5) were differentiated to ILCs following the differentiation protocol II. Cell samples were collected for each stage at days 1, 4, 7, 10, 13, and 17 and analyzed by qRT-PCR for OCT4, ECAD, SOX17, FOXA2, CXCR4, HNF1B, HNF4A, PDX1, HLXB9, NGN3, PAX4, NKX6.1, PAX6, insulin, and glucagon expression. All mRNA expression levels were normalized to the housekeeping gene 18S rRNA expression. Relative gene expression (RQ) was determined by normalization to that in undifferentiated CB-MSC sample at stage 0 (S0) in the dataset and the standard deviation of the gene expression measurements was reported. (D) Flow cytometric staining for the expression of pluripotent stem cell markers, SSEA-3 and SSEA-4 at stage 0 and stage 5 in differentiating CB-MSCs (n = 5). The expression of both these markers was not detected (0%) in CB-MSCs at stage 5, indicating that these cells lose their pluripotency as they progress with the differentiation. expression of HNF4A ( Fig. 5C ), suggesting transition PAX6 by RT-PCR ( Fig. 5C ). PDX1 and NGN3 expression remained constant at stage 5 (Fig. 5C ). PDX1, towards PG. The pancreatic precursor/PG/PE markers PDX1, NGN3, NEUROD1, and NKX6.1 were expressed NKX6.1, and the endocrine progenitor markers NEUROD1 and ISL1 were detected at the protein level at the mRNA and protein levels in stages 3 and 4 (Figs. 5C, 6D-F), reflecting the initial commitment of these in stage 5 (Fig. 7A) . PDX1, NGN3, and NEUROD1 expression at the protein level (40-50%) was observed cells to the endocrine lineage. In stage 4, the PE marker PAX4 could not be detected.
in all stages (S0-S5, data not shown). MAFB expression was observed in stage 4 but declined in stage 5, whereas The appearance of the first endocrine cells at stage 5 was marked by the expression of the TFs MAFA and MAFA expression was observed only in stage 5 at both mRNA and protein levels ( Figs. 5C and 7B) , possibly Differentiated CB-MSCs Produce Endocrine Pancreatic Hormones indicating the differentiation and progressive maturation of insulin-producing cells. Staining for SSEA-3 and SSEA-4 (which was positive in CB-MSCs prior to dif-Endocrine cells that express the pancreatic hormones insulin (INS), glucagon (GCG), and pancreatic polypep-ferentiation) markers was completely negative (SSEA-3: down from ϳ15-25% to 0% and SSEA-4: down from tide (PPY) are generated throughout stage 5 (about 16-18 days of CB-MSC differentiation) (Figs. 5C and ϳ25-35% to 0%) at this stage, as shown in Figure 5D . 8A-C). As determined by IF, the number of PPY-later stages of differentiation (the C-peptide Ab used in this study detects both C-peptide and proinsulin). To expressing cells was relatively high compared to that of GCG-expressing cells (Fig. 8A) . A smaller proportion analyze coexpression of INS and C-peptide, specific areas of the culture were imaged where endocrine cells of endocrine cells derived from CB-MSCs coexpressed INS and GCG or INS and PPY (data not shown), as in small clusters were present primarily in monolayers ( Fig. 8B, C) . reported in hESC-derived endocrine cells (7).
As shown in Figure 5B , islet-like cell clusters (ILCs) Glucose-Induced C-Peptide Release were developed from CB-MSCs at the final stage of difby CB-MSC-Derived Endocrine Cells ferentiation. As the endocrine cells aggregated into clusters of different sizes, the cells in large clusters appeared Glucose sensing and insulin secretion are hallmarks of pancreatic β-cell function. To confirm the de novo smaller than those in small ones. IF staining of ILCs showed the expression of INS and C-peptide (Fig. 8B , synthesis and release of insulin by CB-MSC-derived insulin-expressing cells, we monitored the release of C-C). The expression of C-peptide in these clusters suggests that proinsulin was newly synthesized during the peptide into the culture medium in response to glucose stimulation. Exposure of cells to 20 mM glucose 4) cell aggregates collected from the second differentiation protocol into immunodeficient (NOD/SCID) mice increased the C-peptide release approximately fourfold over basal (2.5 mM) glucose stimulation (9.02 ± 1.37 vs. either IP or under the kidney capsule. Recipient animals were humanely euthanized at different time points after 2.13 ± 0.45 pmol/µg DNA, p < 0.0001) ( Fig. 9A) , in a manner comparable to that of adult human islets (60.00 the procedure, and single-cell suspensions were obtained from spleen, lymph nodes (cervical, mesenteric, and ± 4.54 vs. 14.95 ± 2.00 pmol/µg DNA, p < 0.0001). iliac), thymus, bone marrow, and blood. These samples In Vivo Differentiation of Engrafted CB-MSC-Derived were stained and analyzed for the presence of HLA-Pancreatic Endodermal Cells Into Functional ABC + and CD81 + CB-MSCs by flow cytometry. At 7 Endocrine Cells days posttransplantation, we were able to detect donor cells (ϳ3-6%) in the blood (Fig. 9B-a, B-b ) and bone To provide evidence that CB-MSC-derived pancreatic endoderm can generate functional endocrine cells in marrow (data not shown) but not in the spleen, thymus, or lymph nodes. However, we were unable to track these vivo, we transplanted pancreatic endoderm stage (stage In these ILCs, cells were aggregated into different size clusters and the cells appeared smaller in big clusters than in small clusters. In big ILCs, specific labeling of INS is evidenced by the presence of "ring-like" stain (green arrow) at the rim of the big cluster (B). DAPI (blue) labels cell nuclei. Images were taken using a Leica DM IRB inverted microscope (for A and B, original magnification: 20×). To visualize colocalization of INS and C-PEP in small clusters, images were taken at higher magnification using a Zeiss LSM510 confocal microscope (C, original magnification: 40×). Similar results were obtained in all three CB-MSC clones used for differentiation experiments. (1 KdCp) or injected intraperitoneally (IP)-revealed the presence of HLA-ABC + and CD81 + cells (frequency ϳ3-6%) specific for the transplanted CB-MSCs. (C) Plasma C-peptide levels in transplanted mice. Mice transplanted with CB-MSC-derived pancreatic endocrine (PE) cells or human islets were analyzed at the postengraftment times (day 30, 60, and 150) for the plasma levels of human C-peptide as described in Materials and Methods. C-peptide was not detected in the control group (mice without transplant, n = 3) while a transient increase (ϳ5-20-fold) in the serum levels of human C-peptide was observed in experimental mice (CB-MSC transplantation under kidney capsule, n = 12; by IP injection, n = 2) at both day 60 (p < 0.0885) and day 150 (*p < 0.045) time points. The Ultrasensitive Human C-Peptide ELISA kit (Mercodia) used in this assay has no cross-reactivity to mouse C-peptide and has a detection limit of 1.5 pmol/ml. The reference levels of human C-peptide in normoglycemic nude diabetic mice transplanted with human islets were ϳ55 pmol/ml before (at fasting) and ϳ200 pmol/ml at 60 min after glucose stimulation (not shown). cells at later time points (day 30 and 60). Notably, no 0.0-7.97 pmol/ml). This ϳ5-20-fold increase (transplantation under kidney capsule, n = 12; by IP injection, teratoma formation was observed in CB-MSC recipients at any of the time points of our study. n = 2) at day 150 posttransplant was statistically significant (p < 0.045) (Fig. 9C ). Human C-peptide was always Starting at day 30 after implantation, we assessed glucose-stimulated C-peptide secretion in plasma col-undetectable in the control group (mice without transplant, n = 3). lected from recipient mice. While no human C-peptide could be demonstrated 30 days posttransplantation, low DISCUSSION levels of the protein were detectable around day 60, after a glucose challenge. Measurable levels of human C-Human umbilical cord blood cells are a readily available potential source of insulin-producing cells for trans-peptide were again detected in response to glucose administration at day 150 posttransplantation (range plantation. They are in plentiful supply and can be banked for a wide HLA representation or prospectively show that CB-MSCs express ECAD, SSEA-3, and SSEA-4 in addition to OCT4 (the OCT4 antibody used stored from individuals at birth for future autologous transplantation. Unlike other MSCs, those from the cord in our study is non-cross-reactive with OCT4 isoform B). This observation led us to hypothesize that these blood arise from the youngest possible postnatal tissue, and as such are expected to retain, at least in theory, CB-MSCs might not be fully committed to the mesodermal fate, as is the case with a majority of mesenchymal higher developmental plasticity and potential for replication. Since their procurement is not controversial, they cell types. Such well-documented commitment has been presented as a major roadblock for the design of proto-could have an edge over hES cells provided that they could be instructed to differentiate into insulin-produc-cols aimed at generating of endoderm-derived tissues, such as pancreatic β-cells. In most instances, such efforts ing β-like cells. Detractors of MSC-based approaches, in contrast, argue that these cells are already mesoder-have led to the inefficient induction of mixed phenotypes inconsistent with what we have come to expect of bona mal and therefore cannot be effectively pushed along the true endodermal β-cell lineage.
fide, fully functional β-cells. Our finding that CB-MSCs respond to a chemical β-cell differentiation protocol origi-The CB-MSCs herein described satisfy all three criteria set forth by the International Society for Cell Ther-nally devised for pluripotent cells (7, 34, 42) is novel and indicates that, while sharing key properties and markers apy to define MSCs, namely (i) plastic adherence of the isolated cells in culture and (ii) expression of CD29, with MSCs, these cells are more primitive. The downregulation of "stemness" genes as differentiation progresses CD44, CD73, CD90, and CD105 in greater than 95% of the culture, and lack of expression of markers such as is suggestive that their expression might be associated to the multipotency of CB-MSCs. CD34, CD45. and HLA-DR and (iii) the differentiation potential into fat, bone, and cartilage (12). Our results Expression of TFs implicated in islet development such as ISL1, NKX2.2, NKX6.1, NGN3, PDX1, and confirm other observations (5, 28, 31, 35) that cells with similar cell surface antigen profile can differentiate into NEUROD1 has been reported in undifferentiated, human exocrine pancreas-derived MSCs (3) . At vari-bone, fat, and cartilage, and strongly suggest that they are indeed MSCs. MSCs typically have a limited life ance, expanded MSCs derived from human bone marrow were shown to express NKX6.1 constitutively but span and ultimately undergo replicative senescence, manifested by loss of proliferation and altered morphol-none of the other TFs of the β-cell developmental pathway (44) . In vitro-proliferating human adipose tissue-ogy. Analysis of senescence in our individual colonies and/or CB units suggests remarkable variability, con-derived MSCs were shown to express ISL1, which is a crucial TF for the development of pancreatic endocrine firming observations reported earlier by Kern et al. (28) . Some of our CB-MSC clones expanded up to 20-40 cells (56) . The expression of selected key pancreasspecific TFs has also been recently reported in freshly passages for >6 months without visible changes in either growth pattern or morphology. Although the MSCs isolated CB-MNCs and uninduced/expanded CB-MNCs at early passages (45,46). The first report (46) suggests described here can be cultured and expanded from a relatively low number of CB units (ϳ35%), they can be that the strongly adherent cells grown from CB-MNCs morphologically resemble the MSCs derived from maintained with a normal karyotype for several passages (up to 35) .
human bone marrow and demonstrate the presence of cells expressing NGN3, ISL1, and PAX4, but not PDX1. Archetypal stem cell markers such as NANOG, OCT4, stage-specific embryonic antigens (SSEA-3 and However, there are no immunophenotypical data in this report to unequivocally establish that these CB-MNC-SSEA-4) and tumor rejection antigens (TRA-1-60 and TRA-1-81) were previously thought to be specific to derived adherent cells were MSCs. Similarly, the second report (45) described that freshly isolated CB-MNCs, as very early embryonic development and to hESCs. However, expression of these markers in adult stem cells has well as MSC-like cells derived from CB-MNCs in vitro, express the key pancreatic TFs PDX1, NGN3, ISL1, been documented recently (8,10, 16, 19, 26, 41, 50, 52, 54, 62, 64) . OCT4 is considered a master regulator of hESC brain-4 (BRN4), and PAX6. These cells were not pure MSCs either, as they had markers for both MSCs pluripotency and self-renewal capacities. "Stemness" properties are attributed to OCT4A, one of the two (CD44: 30-36%; CD90: 1-13%) and hematopoietic cells (CD45: 45%). spliced variants of OCT4 gene. The function of the other variant, OCT4B, remains unknown (2,33). While the Here we report, for the first time, that expanded populations of undifferentiated CB-MSCs express the key expression pattern and function of OCT4A in somatic stem cells remain controversial (36,37), Seo et al. dem-pancreatic factors PDX1, NGN3, NEUROD1, NKX6.1, and ISL1 in a relatively large proportion of CB-MSCs. onstrated recently that inhibiting OCT4 in CB-MSCs resulted in decreased cell proliferation and reduced Coexpression of vimentin with NGN3, NEUROD1, and ISL1 was observed in ϳ60-70% of the triple stained multipotency (53) . Expanding upon such findings, we cells, indicating the presence of a subpopulation of cells levels measured in our study could sustain normoglycemia in diabetic mice. This clearly points to the neces-within the undifferentiated CB-MSCs that may be precommitted towards the pancreatic lineage. Of note, sity of qualitatively/quantitatively improving the mass of glucose-responsive, insulin-producing cells before this many of these pancreatic markers are also typically found during neural development (9,11). Therefore, it is approach can be considered for clinical transplantation.
We can only speculate about the differential response important to stress that the mere presence of such markers would not be indicative per se of pancreatic commit-observed in CB-MSCs versus hESCs subjected to the same treatment. In all likelihood these differences are ment. However, the subsequent differentiation of CB-MSCs into insulin-positive, glucose-responsive cells is consis-just a natural consequence of the diverse nature of the starting tissue. Despite the primitiveness of these CB-tent with the above hypothesis.
Mimicking natural pancreatic development is argu-MSCs, one of our most relevant findings is that they express high levels of pancreatic markers such as NGN3 ably the best strategy to produce glucose-responsive, insulin-producing cells in vitro. As previously described or NKX6.1 even before they have been induced to differentiate. From this perspective, a lower-than-expected for hESCs (7,34), we have established that this approach can be used to differentiate CB-MSCs in vitro through relative upregulation of these genes may simply reflect that these cells were not at the same developmental stage stages that resemble definitive endoderm, pancreatic endoderm, and endocrine precursors towards cells that at the initiation of the protocol. However, we cannot assume either that CB-MSCs are equivalent to hES cells produce islet hormones such as insulin, C-peptide, glucagon, and pancreatic polypeptide. Similar to the results at stage 4 of differentiation, because MSCs are not endodermal in origin. In fact, in vitro evidence is insufficient shown for hESCs by Mc Lean et al. (42) , we also demonstrate that inhibition of PI3K signaling efficiently pro-to indicate that these cells are reproducing any native ontogenic/regeneration process, as it is well known that motes differentiation of CB-MSCs into mesendoderm and then definitive endoderm. The differentiation pro-(a) cultures are a poor representation of the in vivo environment where these phenomena take place and (b) cess occurred in a stage-wise fashion, showing a sequential pattern of expression consistent with that observed adaptation of MSCs to growth in plastic is associated with epigenetic changes that invariably distort their during pancreatic development. Unlike previous reports on hESCs (7), our CB-MSC-derived cells made the "normal" physiological responses anyway. Whether or not this process recapitulates a natural one, the fact switch from MAFB + MAFA − to MAFB − MAFA + while maintaining PDX1 and NKX6.1, clearly indicating the remains that the differentiation of CB-MSCs into glucose-responsive, insulin-secreting cells has great poten-maturation of insulin-producing cells in stage 5.
During stage 5 (day ϳ15-18), cells expressing at tial for the development of cell therapies for diabetes. Recent studies demonstrated that autologous transfu-least three out of the five pancreatic endocrine hormones (C-PEP, INS, GCG, and PPY) could be detected. As sion of unmanipulated umbilical CB in subjects with type 1 diabetes at onset is safe (22, 23) and potentially observed by others (7,48), a small number of CB-MSCderived endocrine cells express more than one hormone. beneficial to slow disease progression. These trials were based on the hypothesis that CB cells may improve Though D'Amour et al. observed a robust increase in Cpeptide release to different in vitro responses, the C-outcomes through immunomodulation by selected cell subsets comprising MSCs. The "immunosuppressive" peptide secretion in their cultures was only minimally responsive to glucose (approximately twofold increase property of human MSCs makes them an important candidate for cellular therapy also in allogeneic settings to basal level), similar to that of immature fetal β-cells (7). Our cultures exhibit a stronger response to glucose (30, 58) . CB-stem cells may therefore represent a source of cell precursors with multiple functions, and approaches challenge in vitro.
Previous studies have shown in vivo maturation of encompassing regenerative medicine and immunomodulation could be envisioned. hESC-derived pancreatic precursors obtained using the same differentiation protocols utilized in our study and
The use of CB-MSCs may also offer additional advantages, when compared to hESCs, which include measured as a progressive increase of human C-peptide secretion (both fasting and stimulated) in recipient mice the large availability and ease of procurement, and the possibility of creating large banks that may match most (34) . In our study, transplantation of CB-MSC-derived pancreatic endocrine cell precursors indeed led to mea-or all prospective recipients. Unlike hESCs that are prone to the development of teratomas in vivo (6, 14, 34) , surable C-peptide secretion, but the C-peptide levels were significantly lower than those previously described no teratomas were observed after transplantation of human CB-MSCs in immunodeficient recipients in our for hESC-derived pancreatic precursors generated using similar protocols (34) . Therefore, it is unlikely that the study. This observation, along with the stability of the 
